Baidu
map

泌尿外科

订阅

MedSci主页 / 所有栏目 / 泌尿外科

Oncogene：RASSF10在肾癌中经常表观遗传去激活且其敲除能够促进肿瘤形成

2020-02-24 AlexYang MedSci原创

肾癌甲基化生物标记
关注

肾癌的发生率在全球范围内增加，因此迫切需要靶向治疗和精准医药。之前的研究鉴定和分析了包含10个成员的Ras相关结构域家族，且在人类癌症中经常异常表达。最近，有研究人员建立和分析了Rassf10敲除小鼠模型的相关情况。研究发现，Rassf10单倍体剂量不足能够促进两种小鼠模型（Rassf1A-/-和p53-/-）肿瘤的形成。单倍体剂量不足Rassf10敲除小鼠能够明显的导致各种倾向性疾病，包括淋巴瘤

肾癌的发生率在全球范围内增加，因此迫切需要靶向治疗和精准医药。之前的研究鉴定和分析了包含10个成员的Ras相关结构域家族，且在人类癌症中经常异常表达。最近，有研究人员建立和分析了Rassf10敲除小鼠模型的相关情况。

研究发现，Rassf10单倍体剂量不足能够促进两种小鼠模型（Rassf1A-/-和p53-/-）肿瘤的形成。单倍体剂量不足Rassf10敲除小鼠能够明显的导致各种倾向性疾病，包括淋巴瘤 (Rassf1A-/-背景)和胸腺瘤 (p53-/-背景)。尤其是Rassf10-/-和p53缺陷小鼠表现出比p53-/-对照小鼠多3倍的肾囊肿发生率。更多的是，研究人员发现人类肾癌中，RASSF10经常被CpG岛启动子过甲基化去激活。肾透明细胞原发性肿瘤和乳突状细胞瘤确定了RASSF10甲基化与其表达的减少相关。在独立的数据集中，研究人员确定了RASSF10的去激活与生存的减少和肾癌患者恶化的疾病状态以及多囊肾脏的大小具有临床相关性。功能上讲，研究人员阐释了功能的丧失与KRAS信号的上调和MYC的表达显著相关。

最后，研究人员指出，他们的研究表明了Rassf10可以作为单倍剂量不足肿瘤抑制子的功能。与其他表达结合，RASSF10沉默可以作为肾脏疾病的诊断和预后癌症标记。

原始出处：

Antje M. Richter， Michelle L. Woods， Miriam M. Küster et al. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. Oncogene. 11 Feb 2020

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1809084, encodeId=371818090843e, content=<a href='/topic/show?id=f0f982912b0' target=_blank style='color:#2F92EE;'>#肿瘤形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82912, encryptionId=f0f982912b0, topicName=肿瘤形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Oct 24 17:09:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049274, encodeId=3ecc20492e4d5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 07 19:09:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379899, encodeId=c1f93e989969, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:17 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379898, encodeId=07743e9898bc, content=很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:12 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558180, encodeId=bc6415581802d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 26 13:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-10-24 dzx0922889

    #肿瘤形成#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1809084, encodeId=371818090843e, content=<a href='/topic/show?id=f0f982912b0' target=_blank style='color:#2F92EE;'>#肿瘤形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82912, encryptionId=f0f982912b0, topicName=肿瘤形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Oct 24 17:09:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049274, encodeId=3ecc20492e4d5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 07 19:09:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379899, encodeId=c1f93e989969, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:17 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379898, encodeId=07743e9898bc, content=很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:12 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558180, encodeId=bc6415581802d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 26 13:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-03-07 cy0324

    #Gene#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1809084, encodeId=371818090843e, content=<a href='/topic/show?id=f0f982912b0' target=_blank style='color:#2F92EE;'>#肿瘤形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82912, encryptionId=f0f982912b0, topicName=肿瘤形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Oct 24 17:09:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049274, encodeId=3ecc20492e4d5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 07 19:09:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379899, encodeId=c1f93e989969, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:17 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379898, encodeId=07743e9898bc, content=很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:12 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558180, encodeId=bc6415581802d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 26 13:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-02-29 一天没事干

    很好的学习机会

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1809084, encodeId=371818090843e, content=<a href='/topic/show?id=f0f982912b0' target=_blank style='color:#2F92EE;'>#肿瘤形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82912, encryptionId=f0f982912b0, topicName=肿瘤形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Oct 24 17:09:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049274, encodeId=3ecc20492e4d5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 07 19:09:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379899, encodeId=c1f93e989969, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:17 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379898, encodeId=07743e9898bc, content=很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:12 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558180, encodeId=bc6415581802d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 26 13:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-02-29 一天没事干

    很好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1809084, encodeId=371818090843e, content=<a href='/topic/show?id=f0f982912b0' target=_blank style='color:#2F92EE;'>#肿瘤形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82912, encryptionId=f0f982912b0, topicName=肿瘤形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sat Oct 24 17:09:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049274, encodeId=3ecc20492e4d5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Mar 07 19:09:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379899, encodeId=c1f93e989969, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:17 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379898, encodeId=07743e9898bc, content=很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Feb 29 09:19:12 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558180, encodeId=bc6415581802d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 26 13:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-02-26 zsyan

    #Oncogene#

    0

相关资讯

盘点：肾病研究进展

肾脏的生理功能主要是排泄代谢产物及调节水、电解质和酸碱平衡，分泌多种活性物质，维持机体内环境稳定，以保证机体的正常生理功能。肾炎是由免疫介导的、炎症介质（如补体、细胞因子、活性氧等）参与的，最后导致肾固有组织发生炎性改变，引起不同程度肾功能减退的一组肾脏疾病，可由多种病因引起。在慢性过程中也有非免疫、非炎症机制参与。梅斯医学小编整理了近期肾脏相关疾病的研究进展，与大家一起分享学习！【1

2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新

Immunicum AB（publ）今日公布了一项随机II期临床试验（MERECA研究）的最新结果，该试验在初治转移性肾细胞癌（mRCC）患者中测试了Ilixadencel联合舒尼替尼的有效性和安全性。

Science：儿童肾癌始于胚胎时期

子宫内的遗传变化为儿科肾脏肿瘤的发生奠定了基础。近日，一项发表于《科学》杂志的研究发现，儿童肾癌通常发生于胚胎发育过程中易患癌症的组织。

肾癌靶向药物治疗安全共识

针对晚期肿瘤患者的系统化药物治疗需要同时关注疗效和安全性问题。晚期肾癌治疗的各种靶向药物疗效及适应证范围有所差异，但这类靶向药物在毒性反应谱方面具有独特性和相似性，如何做好靶向药物的不良反应管理对进一步改善瘤控、延缓生命起着不容忽视的重要作用。因此，为进一步提高认识并规范晚期肾癌靶向药物治疗，本共识将从条件保障、人员培训、适应证、治疗方案选择、靶向治疗不良反应管理等方面展开讨论，优化肾癌靶向药物方

Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较

VEGF受体抑制剂对肾细胞癌的治疗具有革命性的意义。之前的研究表明了VEGF受体（VEGFR）酪氨酸激酶抑制剂治疗对经历过就按差点抑制剂治疗的患者有效。因此，研究人员设计了TIVO-3研究来比较tivozanib（一种有效的、选择性的VEGFR抑制剂）和sorafenib在作为三线和四线药物治疗转移肾细胞癌药物的疗效和安全性情况。研究是一个开放标签、随机和对照试验，在12个国家的120个学术性医院

2019 KCRNC共识声明：肾肿块活检在肾癌管理中的作用

2019年12月，加拿大肾脏肿瘤研究网络(KCRNC)发布了肾肿块活检在肾癌管理中的作用的立场声明。诊断性影像学检查的普遍应用使偶发性肾脏小肿块的发现增加，肾脏肿块患者的评估和管理应基于肿块的特征以及患者个体健康状况和表现。本文主要回顾并分析了肾脏肿块活检的证据并对肾脏肿块活检提出指导。

Baidu
map
Baidu
map
Baidu
map